AAIPharma Adds Budapest Team

AAIPharma has expanded its operations in Central and Eastern Europe with the addition of a team in Hungary. The new office is in Budapest and will initially consist of seven staff.

The group in Hungary has therapeutic expertise in the areas of oncology, cardiovascular, respiratory, gastrointestinal and anti-infective clinical trials, along with particular specialist knowledge of pediatric trials. They will provide clinical monitoring, project management and regulatory affairs services across Phase II-IV. AAIPharma already has two other offices in Central and Eastern Europe with operations in Croatia and Russia. With the recent addition of an office in South Africa, AAIPharma now has operations in 14 countries worldwide.

“Central and Eastern Europe is one of most dynamic regions to run clinical trials,” said Ludo Reynders. Ph.D., AAIPharma’s president and chief executive officer. “Hungary with its population of ten million, good hospital infrastructure and the availability of patients is recognised as a key country in this region. As the needs of our biotechnology and pharmaceutical customers to run global clinical trials are ever increasing, it is important that we continue to expand our international presence in key regions such as this to meet these demands.”